INVO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-12), INVO Bioscience's current share price is $0.72. INVO Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.23. INVO Bioscience's Cyclically Adjusted PS Ratio for today is 0.22.
The historical rank and industry rank for INVO Bioscience's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, INVO Bioscience's highest Cyclically Adjusted PS Ratio was 347.23. The lowest was 0.17. And the median was 31.77.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
INVO Bioscience's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.415. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.23 for the trailing ten years ended in Mar. 2024.
The historical data trend for INVO Bioscience's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INVO Bioscience Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 4.26 | 1.32 | 0.26 | 0.43 | 0.35 |
For the Medical Devices subindustry, INVO Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, INVO Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where INVO Bioscience's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
INVO Bioscience's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 0.72 | / | 3.23 | |
= | 0.22 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INVO Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, INVO Bioscience's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.415 | / | 131.7762 | * | 131.7762 | |
= | 0.415 |
Current CPI (Mar. 2024) = 131.7762.
INVO Bioscience Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201212 | 0.000 | 96.871 | 0.000 |
201312 | 0.000 | 98.326 | 0.000 |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.031 | 99.621 | 0.041 |
201506 | 0.046 | 100.684 | 0.060 |
201509 | 0.014 | 100.392 | 0.018 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.084 | 100.470 | 0.110 |
201606 | 0.023 | 101.688 | 0.030 |
201609 | 0.082 | 101.861 | 0.106 |
201612 | 0.045 | 101.863 | 0.058 |
201703 | 0.235 | 102.862 | 0.301 |
201706 | 0.362 | 103.349 | 0.462 |
201709 | 0.308 | 104.136 | 0.390 |
201712 | 0.365 | 104.011 | 0.462 |
201803 | 0.462 | 105.290 | 0.578 |
201806 | 0.478 | 106.317 | 0.592 |
201809 | 0.543 | 106.507 | 0.672 |
201812 | 0.643 | 105.998 | 0.799 |
201903 | 0.781 | 107.251 | 0.960 |
201906 | 2.712 | 108.070 | 3.307 |
201909 | 1.251 | 108.329 | 1.522 |
201912 | 1.348 | 108.420 | 1.638 |
202003 | 1.049 | 108.902 | 1.269 |
202006 | 0.996 | 108.767 | 1.207 |
202009 | 1.355 | 109.815 | 1.626 |
202012 | 0.409 | 109.897 | 0.490 |
202103 | 1.387 | 111.754 | 1.635 |
202106 | 0.398 | 114.631 | 0.458 |
202109 | 0.419 | 115.734 | 0.477 |
202112 | 5.201 | 117.630 | 5.826 |
202203 | 0.270 | 121.301 | 0.293 |
202206 | 0.241 | 125.017 | 0.254 |
202209 | 0.387 | 125.227 | 0.407 |
202212 | 0.457 | 125.222 | 0.481 |
202303 | 0.559 | 127.348 | 0.578 |
202306 | 0.432 | 128.729 | 0.442 |
202309 | 0.549 | 129.860 | 0.557 |
202312 | 0.554 | 129.419 | 0.564 |
202403 | 0.415 | 131.776 | 0.415 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of INVO Bioscience's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Trent D Davis | director | 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204 |
Matthew K Szot | director | 802 NORTH DOUTY STREET, HANFORD CA 93230 |
Steve Shum | director | 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070 |
Andrea Goren | officer: Chief Financial Officer | 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022 |
Barbara Ryan | director | 22 CAVRAY ROAD, NORWALK CT 06855 |
Michael Jos. Campbell | director | 61 SOUTH HILLS DRIVE, BEDFORD NH 03110 |
Rebecca Messina | director | 5582 BROADCAST COURT, SARASOTA FL 34240 |
Jeffrey Segal | director | INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240 |
Awm Investment Company, Inc. | 10 percent owner | 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022 |
Kevin Doody | director, officer: Medical Director | 1109 SOMERSET BLVD, COLLEYVILLE TX 76034 |
Debra Robbins Hoopes | officer: Acting CFO and PFO | 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903 |
Claude Ranoux | 10 percent owner | 8 CHESTNUT STREET, WINCHESTER MA 01890 |
Kathleen T Karloff | director, officer: CEO/Chairman | 109 BEACON STREET UNIT 5, BOSTON MA 02116 |
Bowdring Robert Joseph Jr | officer: Chief Financial Officer | 92 GOULD STREET, WAKEFIELD MA 01880 |
From GuruFocus
By PRNewswire • 08-08-2023
By PRNewswire • 10-23-2023
By PRNewswire • 10-11-2023
By PRNewswire PRNewswire • 03-30-2023
By Business Wire • 10-23-2023
By PRNewswire PRNewswire • 03-27-2023
By PRNewswire • 07-27-2023
By PRNewswire • 08-14-2023
By Marketwired • 10-24-2023
By PRNewswire PRNewswire • 05-08-2023